Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Slavina T, Pecoraro A, Woody GE.

Arch Gen Psychiatry. 2012 Sep;69(9):973-81. doi: 10.1001/archgenpsychiatry.2012.1a.

2.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
3.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
4.

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP.

Arch Gen Psychiatry. 2006 Feb;63(2):210-8.

5.

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP.

N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.

6.

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N.

JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206.

PMID:
29049469
7.

Naltrexone for heroin dependence treatment in St. Petersburg, Russia.

Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.

J Subst Abuse Treat. 2004 Jun;26(4):285-94.

PMID:
15182893
8.

Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.

Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.

J Subst Abuse Treat. 2006 Dec;31(4):319-28. Epub 2006 Jul 24.

PMID:
17084785
9.

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Schottenfeld RS, Chawarski MC, Mazlan M.

Lancet. 2008 Jun 28;371(9631):2192-200. doi: 10.1016/S0140-6736(08)60954-X.

10.

Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, Burakov A, Masalov D, Romanova TN, Palatkin V, Tyurina A, Yaroslavtseva T, Sinha R, Kosten TR.

Drug Alcohol Depend. 2013 Oct 1;132(3):674-80. doi: 10.1016/j.drugalcdep.2013.04.021. Epub 2013 May 15.

11.

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL.

Addiction. 2013 Sep;108(9):1628-37. doi: 10.1111/add.12208. Epub 2013 May 24.

PMID:
23701526
12.

[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].

Krupitskiĭ EM, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Blokhina EA, Silverman BL.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(5 Pt 2):3-11. Russian.

PMID:
22951790
13.

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M.

JAMA Psychiatry. 2015 May;72(5):430-7. doi: 10.1001/jamapsychiatry.2014.3053.

PMID:
25760804
14.

Long-acting depot formulations of naltrexone for heroin dependence: a review.

Krupitsky EM, Blokhina EA.

Curr Opin Psychiatry. 2010 May;23(3):210-4. doi: 10.1097/YCO.0b013e3283386578. Review.

PMID:
20224403
15.

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ; PRO-814 Study Group.

JAMA. 2016 Jul 19;316(3):282-90. doi: 10.1001/jama.2016.9382.

PMID:
27434441
16.

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL.

JAMA. 2010 Oct 13;304(14):1576-83. doi: 10.1001/jama.2010.1427.

PMID:
20940383
17.

Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.

Brooks AC, Comer SD, Sullivan MA, Bisaga A, Carpenter KM, Raby WM, Yu E, O'Brien CP, Nunes EV.

J Clin Psychiatry. 2010 Oct;71(10):1371-8. doi: 10.4088/JCP.09m05080ecr. Epub 2010 Jul 13.

18.

Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Yaroslavtseva T, Pecoraro A, Woody G.

Am J Drug Alcohol Abuse. 2016 Sep;42(5):614-620. Epub 2016 Jul 19.

19.

Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

Syed YY, Keating GM.

CNS Drugs. 2013 Oct;27(10):851-61. doi: 10.1007/s40263-013-0110-x. Review.

PMID:
24018540
20.

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.

Alcohol Clin Exp Res. 2006 Mar;30(3):480-90.

PMID:
16499489

Supplemental Content

Support Center